


PROSPECTUS SUPPLEMENT TO THE BASE PROSPECTUS DATED JULY 17, 2020 IN RESPECT OF THE FINAL TERMS DATED OCTOBER 1, 2020 RELATING TO THE ISSUE OF UP TO PLN 100,000,000 TWO-YEAR SIX-MONTH QUANTO PLN WORST OF MEMORY DIGITAL COUPON NOTES ON THE ORDINARY SHARES OF ASTRAZENECA PLC, BAYER AG, BIOGEN INC., GILEAD SCIENCES, INC., SANOFI AND VERTEX PHARMACEUTICALS INCORPORATED, DUE MAY 10, 2023 (ISIN: XS2106002483) (TRANCHE 463641)



**GOLDMAN, SACHS & CO. WERTPAPIER GMBH**  
*(Incorporated with limited liability in Germany)*

**as Issuer**

**GOLDMAN SACHS FINANCE CORP INTERNATIONAL LTD**  
*(Incorporated with limited liability in Jersey)*

**as Issuer**

**GOLDMAN SACHS INTERNATIONAL**  
*(Incorporated with unlimited liability in England)*

**as Issuer and, in respect of certain Securities only, as Guarantor**

**THE GOLDMAN SACHS GROUP, INC.**  
*(A corporation organised under the laws of the State of Delaware)*

**in respect of certain Securities only, as Guarantor**

**SERIES P PROGRAMME FOR THE ISSUANCE OF  
WARRANTS, NOTES AND CERTIFICATES**

### **This Prospectus Supplement**

This prospectus supplement (the "**Prospectus Supplement**") to the base prospectus dated July 17, 2020 prepared by Goldman, Sachs & Co. Wertpapier GmbH ("**GSW**") as issuer, Goldman Sachs Finance Corp International Ltd ("**GSFCI**") as issuer, Goldman Sachs International ("**GSI**") as issuer and as guarantor in respect of certain Securities only and The Goldman Sachs Group, Inc. ("**GSG**") as guarantor in respect of certain Securities only (the "**Original Base Prospectus**") under their Series P programme for the issuance of warrants, notes and certificates with respect to the securities (the "**Programme**"), constitutes a supplement to the Base Prospectus for the purposes of Article 23(1) of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and should be read in conjunction with Prospectus Supplement No. 1 to the Original Base Prospectus dated August 4, 2020, Prospectus Supplement No. 2 to the Original Base Prospectus dated August 21, 2020 and Prospectus Supplement No. 3 to the Original Base Prospectus dated August 31, 2020 (the Original Base Prospectus as so supplemented, the "**Base Prospectus**"). On July 17, 2020, the *Commission de Surveillance du Secteur Financier* (the "**CSSF**") approved the Base Prospectus for the purposes of Article 6 of the Luxembourg Law dated July 16, 2019 on prospectuses for securities.

Terms defined in the Base Prospectus have the same meaning when used in this Prospectus Supplement unless otherwise defined herein. This Prospectus Supplement shall form part of and be read in conjunction with the Base Prospectus.

This supplement is available on the website of the Luxembourg Stock Exchange at [www.bourse.lu](http://www.bourse.lu) and <https://classic.gs.de/pl/XS2106002483>.

### **Purpose of this Supplement**

The purpose of this Supplement is to amend the information contained in the Final Terms dated October 1, 2020 (the "**Final Terms**") relating to the issue of up to PLN 100,000,000 Two-Year Six-Month Quanto PLN Worst of Memory Digital Coupon Notes on the ordinary shares of AstraZeneca Plc, Bayer AG, BIOGEN INC., Gilead Sciences, Inc., Sanofi and Vertex Pharmaceuticals Incorporated, due May 10, 2023 (ISIN: XS2106002483) (Tranche 463641) (the "**Securities**") in order to revise the composition of the Share Basket in respect of the Final Terms. **This Prospectus Supplement supplements the Base Prospectus only as it relates to the Securities and shall only amend information in the Final Terms for the Securities.**

### **Rights of withdrawal**

In accordance with Article 23(2) of the Prospectus Regulation, investors who have already agreed to purchase or subscribe for the Securities before this Prospectus Supplement is published have the right exercisable until October 9, 2020, which is two working days after the publication of this Prospectus Supplement, to withdraw their acceptances.

### **Information being supplemented**

#### ***Amendments to the Final Terms and the Issue-Specific Summary***

The Final Terms and the Issue-Specific Summary are amended and supplemented as follows:

#### **1. *Amendments to the information contained in the Final Terms for the Securities***

- 1.1 The title of the Final Terms on page 1 shall be deleted in its entirety and replaced with: "Issue of up to PLN 100,000,000 Two-Year Six-Month Quanto PLN Worst of Memory Digital Coupon Notes on the ordinary shares of AstraZeneca Plc, Bayer AG, BIOGEN INC., Gilead Sciences, Inc. and Sanofi, due May 10, 2023 (the "**Notes**" or the "**Securities**")".
- 1.2 The Underlying Asset Table in paragraph 51 of the Contractual Terms shall be deleted in its entirety and replaced with the following:

<b>UNDERLYING ASSET TABLE</b>			
<b>Underlying Asset</b>	<b>Bloomberg / Reuters</b>	<b>ISIN</b>	<b>Exchange</b>
The ordinary shares of AstraZeneca Plc	AZN LN <Equity> / AZN.L	GB0009895292	London Stock Exchange
The ordinary shares of Bayer AG	BAYN GY <Equity> / BAYGn.DE	DE000BAY0017	XETRA
The ordinary shares of BIOGEN INC.	BIIB UW <Equity> / BIIB.OQ	US09062X1037	NASDAQ Global Select Market
The ordinary shares of Gilead Sciences, Inc.	GILD UW <Equity> / GILD.OQ	US3755581036	NASDAQ Global Select Market
The ordinary shares of Sanofi	SAN FP <Equity> / SASY.PA	FR0000120578	Euronext Paris

- 1.3 The reference in paragraph 76 of the Contractual Terms to "October 1, 2020" shall be deleted and replaced with "October 7, 2020".
- 1.4 The reference in the section, "Offer Period", in paragraph 9 of the Other Information, to "October 1, 2020" shall be deleted and replaced with "October 7, 2020".

2. ***Amendments to the information contained in the Issue-Specific Summary for the Securities***

- 2.1 The "Securities" section of the Issue-Specific Summary of the Securities under the heading, INTRODUCTION AND WARNINGS, shall be deleted in its entirety and replaced with the following:

<b>Securities:</b> Issue of up to PLN 100,000,000 Two-Year Six-Month Quanto PLN Worst of Memory Digital Coupon Notes on the ordinary shares of AstraZeneca Plc, Bayer AG, BIOGEN INC., Gilead Sciences, Inc. and Sanofi, due May 10, 2023 (ISIN: XS2106002483) (the " <b>Securities</b> ").
---

- 2.2 The Underlying Asset Table in the "Rights attached to the Securities" section of the Issue-Specific Summary of the Securities under sub-heading, "What are the main features of the Securities?" under the heading, KEY INFORMATION ON THE SECURITIES, shall be deleted in its entirety and replaced with the following:

<b>Underlying Asset or Share</b>	<b>Bloomberg / Reuters / ISIN</b>	<b>Exchange</b>
The ordinary shares of AstraZeneca Plc	AZN LN <Equity> / AZN.L / GB0009895292	London Stock Exchange
The ordinary shares of Bayer AG	BAYN GY <Equity> / BAYGn.DE / DE000BAY0017	XETRA
The ordinary shares of BIOGEN INC.	BIIB UW <Equity> / BIIB.OQ / US09062X1037	NASDAQ Global Select Market
The ordinary shares of Gilead Sciences, Inc.	GILD UW <Equity> / GILD.OQ / US3755581036	NASDAQ Global Select Market
The ordinary shares of Sanofi	SAN FP <Equity> / SASY.PA / FR0000120578	Euronext Paris

- 2.3 The reference in the "Terms and conditions of the offer" section of the Issue-Specific Summary of the Securities under sub-heading, "Under which conditions and timetable can I invest in this Security?" under the heading, KEY INFORMATION ON THE OFFER OF THE SECURITIES TO THE PUBLIC AND/OR THE ADMISSION TO TRADING ON A REGULATED MARKET, to "October 1, 2020" shall be deleted and replaced with "October 7, 2020".

**Responsibility**

Each of GSI, GSW, GSFCI and GSG accepts responsibility for the information given in this Prospectus Supplement and confirms that, having taken all reasonable care to ensure that such is the case, the information contained in this Prospectus Supplement is, to the best of their knowledge, in accordance with the facts and does not omit anything likely to affect its import.

**Interpretation**

To the extent that there is any inconsistency between (a) any statement in this Prospectus Supplement and (b) any other statement in or incorporated by reference into the Base Prospectus, the statements in (a) above will prevail.

**U.S. notice**

This Prospectus Supplement is not for use in, and may not be delivered to or inside, the United States.

---

The date of this Prospectus Supplement is October 7, 2020.

353497185(Ver3)/Ashurst(BJANG)/AGS